MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$62,920K
Free Cash flow
$25,940K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Net income (loss)
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts receivable
Proceeds from exercise of common...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
31,378
43,358
26,013
-48,481
Depreciation and amortization
514
509
502
1,006
Accretion of premium/discount on marketable securities
221
1,192
371
1,954
Non-cash lease expense
149
123
120
364
Amortization of debt issuance costs
8
9
9
17
Operating lease liabilities
-
-
-115
-74
Stock-based compensation expense
16,056
11,471
9,998
24,377
Accrued clinical trial site costs
-
-
-
37
Change in fair value of stock warrants
-
0
-
-
Change in fair value of contingent consideration
484
854
614
4,068
Other non-cash reconciling items
28
13
-14
-16
Accounts receivable
18,931
2,702
882
24,624
Inventory
1,831
8,020
3,916
2,095
Prepaid expenses, other current assets and other assets
-780
3,451
948
339
Accounts payable
-2,970
4,286
1,929
-2,603
Accrued compensation
-3,954
2,429
981
1,491
Operating lease liabilities
-133
-308
-
-
Essentialis acquisition milestone payments
2,954
-
-
-
Other liabilities
7,633
1,162
9,543
3,434
Net cash provided by (used in) operating activities
25,980
48,704
43,454
-45,360
Purchases of property and equipment
40
58
1
14
Purchases of marketable securities
101,268
187,840
163,172
104,764
Maturities of marketable securities
139,291
62,538
71,730
119,800
Net cash provided by investing activities
37,983
-125,360
-91,443
15,022
Proceeds from the sale of common stock, net of issuance costs
-
0
215,721
-
Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
-
0
-
-
Proceeds from issuance of debt, net of issuance costs
-
0
-
-
Payment for repurchase of common stock
4
100,146
-
-
Payment of debt issuance costs
0
0
0
62
Proceeds from exercise of common stock and pre-funded stock warrants
-
5,187
-
-
Proceeds from exercise of common stock warrants
-5,187
-
0
5,187
Proceeds from exercise of stock options
52
954
2,255
13,993
Tax withholding payments for net share-settled equity awards
1
708
0
33
Payment of deferred financing costs
-
-
-
178
Essentialis acquisition milestone payments
1,090
-
-
-
Net cash provided by (used in) financing activities
-1,043
-99,900
218,154
18,907
Net increase (decrease) in cash and cash equivalents
62,920
-176,556
170,165
-11,431
Cash and cash equivalents, beginning of period
70,106
246,662
87,928
-
Cash and cash equivalents, end of period
133,026
70,106
246,662
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$139,291K
Net income (loss)
$31,378K
Stock-based compensation
expense
$16,056K
Other liabilities
$7,633K
Prepaid expenses, other
current assets and other...
-$780K
Depreciation and
amortization
$514K
Change in fair value of
contingent consideration
$484K
Non-cash lease expense
$149K
Amortization of debt issuance
costs
$8K
Net cash provided by
investing activities
$37,983K
Net cash provided by
(used in) operating...
$25,980K
Canceled cashflow
$101,308K
Canceled cashflow
$31,022K
Net increase
(decrease) in cash and cash...
$62,920K
Canceled cashflow
$1,043K
Purchases of marketable
securities
$101,268K
Purchases of property and
equipment
$40K
Accounts receivable
$18,931K
Accrued compensation
-$3,954K
Accounts payable
-$2,970K
Essentialis acquisition
milestone payments
$2,954K
Inventory
$1,831K
Accretion of
premium/discount on marketable...
$221K
Operating lease
liabilities
-$133K
Other non-cash
reconciling items
$28K
something is missing
$5,187K
Proceeds from exercise of
stock options
$52K
Net cash provided by
(used in) financing...
-$1,043K
Canceled cashflow
$5,239K
Proceeds from exercise of
common stock warrants
-$5,187K
Essentialis acquisition
milestone payments
$1,090K
Payment for repurchase
of common stock
$4K
Tax withholding
payments for net...
$1K
Buy us a coffee
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)